Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, by mutual consent with the Company, and the search for his successor is ongoing. Dr. Dohrmann has served as Chief Scientific Officer and Member of the Management Board since 2010, a tenure of 16 years. Chief Executive Officer Dr. Christian Wojczewski credited Dr. Dohrmann with strengthening Evotec's scientific excellence and innovation culture and with establishing key capabilities across its platforms, including iPSC-based technologies and omics capabilities, adding that the science infrastructure he built will be an essential component of Evotec's future growth and profitability. Dr. Dohrmann said the process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years and that he was privileged to contribute to that progress. Evotec, a life science company working with all Top 20 Pharma companies and over 800 biotechs, employs around 4,500 experts across sites in Europe and the U.S.
Evotec SECSO Cord Dohrmann to step down by mutual consent in 2026; no clear positive or negative driver stated.
